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TRM 24% 10% 0.06
Relapse 43% 36% 0.5
OS 39% 62% 0.02
DFS 34% 54% 0.04
Abstracts / Biol Blood Marrow Transplant 19 (2013) S211eS232S226Methods: A retrospective review of the patients who
relapsed following an allogeneic HCT for a myeloid malig-
nancy at Mayo Clinic in Arizona was performed. The BM
sample closest in time prior to relapse was identiﬁed and the
morphologic, ﬂow cytometric, karyotypic, FISH, PCR and
chimerism results were reviewed.
Results: Out of 187 patients with a myeloid malignancy, 40
(31 AML, 4 MPN blast crisis, 4 MDS, 1 CML) relapsed at
a median of 113 days (range 22-820 days) after HCT. Thirty
percent of the relapses occurred after a myeloablative HCT.
Donor type was equally distributed between matched
related and mismatched/ matched unrelated donors. A
cytogenetic and molecular marker with the diagnosis was
identiﬁable in 22/40 and 6/40 patients respectively. 18/40
patients had residual disease present at HCT. 13/40 patients
showed an early relapse within the ﬁrst 90 days. In the
remaining patients, time between the last BM and relapse
ranged from 38-184 days (median 69). Abnormal results
were found only in 9/27 patients in the preceding BM and
included abnormal cytogenetic clone identical to diagnosis in
2 patients; abnormal RT-PCR for BCR/ABL in 1, cytogenetic
abnormality in donor cell line in 3, and decreased chime-
risms in unsorted marrow cells in 3 patients.
Conclusions: A 3-month monitoring schedule of BM evalu-
ation using the currently available tools had low sensitivity
to predict relapse. Findings that may justify intervention
were rare (less than 10% of patients), and were restricted to
abnormal cytogenetic and abnormal RT-PCR results. The
clinical signiﬁcance of cytogenetic abnormalities observed in
donor cells is not clear. Our ﬁndings emphasize that until the
optimal surveillance technique and schedule can be deﬁned
and standardized, more frequent use of pre-emptive therapy
in patients at high risk of relapse may be of beneﬁt.228
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Reduced intensity conditioning (RIC) with ﬂudarabine
(Flu) and sub-myeloablative doses of busulfan (Bu) (<8 mg/
kg) has low transplant related mortality (TRM) compared to
myeloablative (MA) conditioning, and is increasingly utilized
in older and medically inﬁrm pts. Flu with MA Bu (>8mg/kg)
using pharmacokinetic (PK) dosing also has low TRM, but
randomized comparisons to RIC are lacking. Therefore, we
compared RIC and MA FluBu dosing on TRM, relapse and
survival in remission AML. We reviewed AML pts receiving
allogeneic hematopoietic stem cell transplant (HSCT) in
remission (CR1/CR2) at the University of Michigan from 2003
e 2011. RIC (FluBu2) was ﬂu 40mg/m2 x 4 days with IV Bu 3.2
mg/kg x 2 days. FluBu2 included TLI/TBI (200cGy) in 39% of
cases, and ATG in one case. MA (FluBu4) was ﬂu 40mg/m2 x 4
days with IV Bu 3.2 mg/kg x 4 days with PK adjustment to
a target Css of 600-900 mcg/L (Seattle PK lab). FluBu4 had no
TBI/TLI/ATG. Pt <18 yrs, cords, prior HSCT and active AMLwere excluded. Cumulative incidence of GVHD, TRM and
relapse were calculated with competing risks. A total of 122
pts (FluBu2¼71; FluBu4¼51) were identiﬁed. Most primary
GVHD prophy was tacro + MMF for FluBu2 (89%), and tacro +
MTX for FluBu4 (86%). FluBu2 pts were older (60 vs. 51; P <
.01), but donor type, HLA match, and disease risk (cytoge-
netics / FLT3 ITD) were not signiﬁcantly different. There was
a trend towards higher ( 3) comorbidity index scores in
FluBu2 (42% vs. 25%; P ¼ .09). All FluBu4 pts engrafted; two
graft failures occurred (3%) in FluBu2. TRM did not differ at
day 100 (FluBu2¼0% vs. FluBu4¼2%; P ¼ .3) or 1 yr
(FluBu2¼17% vs. FluBu4¼10%; P ¼ .3), but by 3 yrs there was
a trend towards greater TRM in FluBu2 (FluBu2¼24% vs.
FluBu4¼10%; P ¼ .06). After adjusting for donor type, HLA
match, age, and HSCT-CI the trend for greater TRM in FluBu2
remained (HR: 3.5, P ¼ .04, 95% CI: 1.1 e11.0). Pts with HSCT-
CI  3, had similar TRM with FluBu2 (HR: 1.5, P ¼ .6, 95% CI:
0.4 e 5.7). Acute GVHD grade II-IV was not signiﬁcantly
different between FluBu2 and FluBu4 (38% vs. 24%; P ¼ .09).
Chronic GVHD caused late deaths in 10% of FluBu2, and in 4%
of FluBu4. There was no signiﬁcant difference in relapse at 3
yrs (FluBu2¼43% vs FluBu4¼36%, P ¼ .5). Overall survival
(OS) favored FluBu4 compared to FluBu2 (OS: 62% vs. 39%; P
¼ .02). This difference in OS was greater in intermediate risk
AML (74% vs 50%; P¼ .07), compared to high risk AML (40% vs
28%, P ¼ .5). FluBu4 pts had a non-signiﬁcant OS advantage
after multivariate analysis including donor type, HLA match,
and disease risk (HR: 1.75, P ¼ .06, 95% CI: 1.0 e 3.1). In
summary, MA conditioning with FluBu4 did not increase
TRM compared to RIC with FluBu2. The potential survival
beneﬁt of FluBu4 in remission AML requires prospective
validation.229
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Background: IFD is a major cause of morbidity andmortality
after intensive chemotherapy and HSCT in patients with
hematologic malignancies. MBL is a member of the C-type
lectin superfamily of microbe pattern recognition molecules.
Several studies have suggested an association of MBL levels
below 1,000 ng/ml with a variety of infectious complications
in cancer therapy, but there are conﬂicting data. The aim of
this study was to investigate the association between low
MBL levels and the development of IFD in patients with
hematologic malignancies undergoing chemotherapy or
HSCT.
No IFD Proven or Probable IFD
MBL>1000 79 (84.9%) 14 (15.1%)
MBL<1000 52 (88.1%) 7 (11.9%)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S211eS232 S227Methods: We conducted an analysis of MBL levels among
patients enrolled in a previous prospective cohort study.
Serum samples from 152 patients with hematologic malig-
nancies who received chemotherapy and/or HSCT between
December 2001 and November 2006 were collected before
or early after treatment initiation and stored at -70oC.
Quantiﬁcation of MBL levels was performed by a sandwich-
ELISA assay (Viracor-IBT laboratories, Mo). Patients were
followed for 6 months and scored as developing proven or
probable IFD or not. The relationship between MBL level and
developing proven or probable IFD was assessed using chi-
square and Mann-Whitney tests. Survival analyses including
logistic regression and Cox Proportional Hazards models
were used to test the effect of MBL level and IFD status on
overall survival and whether MBL level has an effect on IFD-
free survival time.
Results: Forty-ﬁve of 152 patients (29.6%) developed IFD
during the 6 months follow-up period of which 21 (46.7% of
IFD cases and 13.8% of patients) were proven or probable IFD.
Fifty-nine of 152 patients (38.8%) hadMBL levels below 1,000
ng/ml. The rates of proven or probable IFD in patients with
MBL levels belowand above 1,000 ng/mLwere 11.9% and 15.1
% respectively (P¼.579). Mean MBL levels were lower in the
IFD-free group (2085 vs 2398, p¼.429). MBL levels below
1,000 ng/ml were not a predictor of death (P¼.233). Mean
IFD- free survival times in patients with MBL levels below
and above 1,000 ng/ml were 20 weeks and 21 weeks
respectively (P¼.423). As expected, proven or probable IFD
was associated with death (P<.0001).
Conclusions: Our ﬁndings indicate that lowMBL levels were
not associatedwith an increased risk of developing proven or
probable IFD or overall survival in patients with hematologic
malignancy.
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Background: In relapsed or refractory AML allogeneic
transplantation (HCT) is considered to be the only chance to
achieve long-term survival but still only about 40% of
younger patients receive allogeneic HCT. Moderate activity of
salvage regimens and accumulating toxicity of chemo-
therapy are reasons that may prevent from transplantation.
Our goal was to study the safety and efﬁcacy of a clofarabine
salvage therapy prior to allogeneic HCT. Here, we report data
from patients of stage I of a two-stage phase II study.
Patients and Methods: Patients above the age of 40 with
relapsed or refractory AML who were ﬁt for allogeneic HCT
were eligible to participate in this multicenter, single-arm
study. All patients received at least one cycle of clofarabine40 mg/m2 followed by intermediate dose cytarabine 1 g/m2
days 1-5 (CLARA). Patients with a donor who exposed at least
a reduction of leukemic blasts were scheduled for allogeneic
HCT in aplasia after CLARA. The conditioning regimen con-
sisted of clofarabine 30 mg/m2 on days -6 to -3 and
melphalan 140 mg/m2 on day -2. Cyclosporine in combina-
tion with MMF was used for GvHD prophylaxis. In patients
with partially matched unrelated donors the administration
of ATG was recommended. Primary endpoint was treatment
success deﬁned as a complete remission (CR, CR(i)) six weeks
after completion of therapy.
Results: Twenty-six patients were enrolled into stage I of
this trial. Median age was 60 years. Fifty percent of the
patients each had refractory or relapsed AML. At early
response assessment on day 15 after CLARA-1 13 patients
(50%) had less than 10% marrow blasts. Ten patients (38%)
showed a reduction in marrow cellularity or blast
percentage. Two patients did not have a signiﬁcant marrow
blast reduction. One patient died after the ﬁrst cycle CLARA
from septic multi-organ failure. Twenty-two patients (85%)
received allogeneic HCT within this trial. Donors were HLA-
identical siblings in 5 patients (23%), HLA-compatible unre-
lated donors in 11 patients (50%) and unrelated donors with
onemismatch in 6 patients (27%). Liver toxicity was themost
frequent adverse event. Seventeen patients (65%) developed
grade III liver enzyme elevationwhile Grade IV was observed
in 1 patient. Grad III/IV GvHD occurred in 6 patients (27%). All
26 patients have been evaluated for the primary endpoint.
Sixteen patients had a CR (62%) and 6 patients a CRi (23%) at
ﬁnal response evaluation.
With amaximum follow up of 19months 16 patients have
died (7 patients died after relapse). At present 10 patients are
alive, 6 of them had refractory disease.
Conclusion: Salvage therapy with CLARA and subsequent
conditioning with clofarabine and melphalan prior to allo-
geneic HCT provides good anti-leukemic activity in patients
with relapsed or refractory AML. The CR rate of the ﬁrst 26
patients was evaluated favorably and the trial is currently
recruiting into stage 2.231
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Background: Good risk AML patients (core binding factor
AML; diploid cytogenetics AML without Flt-3 ITD) are
frequently consolidated with 3-4 cycles of high dose cytar-
abine (HIDAC) after induction of remission. About 50% of
these patients relapse resulting in long term survival of 40-
60% (Marcucci et al. JCO vol. 23 :5705-5717; 2005).
Materials and Methods: We retrospectively analyzed the
outcomes of patients with good risk AML who underwent
ASCT since 2009.
Results: 17 patients (10 males; 7 females) were identiﬁed in
the database. Their median age was 60 years (range 29-80).
All patients had received HIDAC based induction followed by
at least one cycle of HIDAC based consolidation. Mobilizing
